[Cetuximab improved the poor performance status of a colorectal cancer patient].
Copyright policy )[Cetuximab improved the poor performance status of a colorectal cancer patient].
A 60-year-old man with unresectable colon cancer required treatment for hydronephrosis, acute cholecystitis, and obstructive jaundice before chemotherapy. His performance status (PS) gradually deteriorated to PS 4. Cetuximab monotherapy was initiated instead of intensive chemotherapy. His general condition improved and mFOLFOX7 therapy was then continued in addition to cetuximab. A computed tomography (CT) scan after 6 months of chemotherapy revealed a partial response (PR). Cetuximab monotherapy may contribute to the treatment of patients with a poor PS.
- Kansai Rosai Hospital Japan
Male, Liver Neoplasms, Cetuximab, Adenocarcinoma, Middle Aged, Antibodies, Monoclonal, Humanized, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Neoplasm Staging
Male, Liver Neoplasms, Cetuximab, Adenocarcinoma, Middle Aged, Antibodies, Monoclonal, Humanized, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Neoplasm Staging
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!